Shire's Vyvanse Will Attain Blockbuster Status by 2017 in the Attention-Deficit/Hyperactivity Disorder Drug Market
Emerging Nonstimulant Drugs Will Earn Less Than 15 Percent Share of the ADHD Market in 2017, According to a New Report from Decision Resources
Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that Shire's recently launched stimulant Vyvanse will become only the third blockbuster in attention-deficit/hyperactivity disorder (ADHD), helping to ensure that Shire's impressive ADHD portfolio will dominate this market through 2017.
The new Pharmacor report entitled Attention-Deficit/Hyperactivity Disorder finds that Vyvanse will garner US$1.2 billionin sales in 2017, owing in large part to the drug's robust efficacy, its approval for both children and adults, and its lower abuse potential compared with other first-line psychostimulants. Vyvanse and other Shire products, including Daytrana and the emerging nonstimulant agent Intuniv, will help secure Shire's dominance of the ADHD market, where it will hold a commanding 44 percent total market share in 2017 inthe United States,France,Germany,Italy,Spain, theUnited KingdomandJapan. Shire's dominance will be maintained in spite of steep losses to generic competition in 2009 inthe United Statesfor its market-leading product, Adderall XR.
The report also finds that emerging nonstimulant drugs will earn less than 15 percent share of the ADHD market in 2017.
Other news from the department research and development
